Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430061 | 0.90 | ESR2 (0.69) | ESR1ESR2 | |
| SCHEMBL5432083 | 0.89 | ESR1 (0.66) | ESR1ESR2 | |
| SCHEMBL5426492 | 0.88 | ESR2 (0.67) | ESR1ESR2 | |
| SCHEMBL5427983 | 0.86 | ESR2 (0.69) | ESR1ESR2 | |
| SCHEMBL5421745 | 0.80 | ESR2 (1.00) | ESR1ESR2 | |
| SCHEMBL5726183 | 0.79 | ESR1 (0.68) | ESR1ESR2 | |
| SCHEMBL5430390 | 0.79 | ESR2 (0.69) | ESR1ESR2 | |
| SCHEMBL5338464 | 0.78 | ESR1 (0.52) | ESR1ESR2 | |
| SCHEMBL5336152 | 0.77 | ESR1 (0.53) | ESR1ESR2 | |
| SCHEMBL5428187 | 0.77 | ESR2 (0.71) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191438-A1 | Methods for the treatment of hypertension | ROHRER SUSAN P | 2007-08-16 | — | — | US | claimed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1339683-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | claimed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20070191438-A1 | Methods for the treatment of hypertension | ROHRER SUSAN P | 2007-08-16 | — | — | US | disclosed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191438-A1 | Methods for the treatment of hypertension | EDNRA, GPER1, EDNRB | ESR1 13/4885ESR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.